Rabia Gurses Ozden - Jul 1, 2022 Form 3 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)

Role
Chief Medical Officer
Signature
/s/ Donald Notman, Attorney-in-Fact for Rabia Gurses Ozden
Stock symbol
OCUL
Transactions as of
Jul 1, 2022
Transactions value $
$0
Form type
3
Date filed
7/11/2022, 08:55 PM
Previous filing
Mar 18, 2022
Next filing
Feb 1, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding OCUL Common Stock 45.6K Jul 1, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding OCUL Stock Option (right to buy) Jul 1, 2022 Common Stock 100K $18.70 Direct F2
holding OCUL Stock Option (right to buy) Jul 1, 2022 Common Stock 20K $18.70 Direct F3
holding OCUL Stock Option (right to buy) Jul 1, 2022 Common Stock 137K $5.27 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 3, 2022, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service to the Company, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on February 3, 2023, and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter.
F2 On February 1, 2021, the reporting person was granted an option to purchase 100,000 shares of the Company's common stock, vesting over four years, with 1/4 of the shares underlying the option vesting on February 1, 2022, and 1/48 of the shares underlying the option vesting monthly thereafter.
F3 On February 1, 2021, the reporting person was granted an option to purchase 50,000 shares of the Company's common stock. The option vests in four installments based on the Company's satisfaction of certain performance criteria. The performance criteria for the first two installments were met on or prior to December 31, 2021, resulting in the vesting of the option as to 20,000 shares.
F4 On February 3, 2022, the reporting person was granted an option to purchase to 136,667 shares of the Company's common stock, vesting over four years, with 1/48 of the shares underlying the option vesting monthly beginning on the one-month anniversary of the date of grant.

Remarks:

Exhibit List Exhibit 24 - Power of Attorney